European Companies Search Engine
EU funding (€7,459,254): Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases Hor1 Jan 2024 EU Research and Innovation programme "Horizon"
Overview
Text
Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases
"The European Consortium ""Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases"" (AVITHRAPID) aims to support the search for novel broad-spectrum antiviral compounds by advancing multiple approaches. Building on a pre-existing set of bioactive small molecules, which are at least at the validated hit level, AVITHRAPID strives for the development of pre-clinical candidates targeting several viruses. This will be achieved by combining the relevant expertise for pre-clinical drug discovery, including molecular modeling, biochemical and cell-based assays, X-ray crystallography, medicinal chemistry, biophysical binding studies, ADMETox profiling, in vitro and in vivo PK, as well as animal disease models. In addition, the consortium aims to conduct a Phase 2a clinical trial for a small molecule developed against Zika virus. Moreover, the consortium aims to identify and validate further viral targets and thereby contribute to the search for novel antiviral targets. As a consequence of the activities in AVITHRAPID, an early-stage drug discovery pipeline will be established that can be used to rapidly identify and develop novel antiviral compounds against emerging diseases."
Funded Companies:
Source: https://cordis.europa.eu/project/id/101137192
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: CHELONIA SA, Lugano, Switzerland.
The visualizations for "CHELONIA SA - EU funding (€7,459,254): Antiviral Therapeutics for Rapid Response Against Pandemic Infectious Diseases"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
